Key result
A serum biomarker panel consisting of AAT, TRSF, HDLC, and APOA1 effectively distinguished MDD patients with suicidal ideation from those without suicidal ideation (AUC 0.928).
Why the study?
Major depressive disorder and suicide are major health problems, but objective methods to diagnose MDD or suicidal ideation are lacking.
Does a serum biomarker panel (AAT, TRSF, HDLC, APOA1) accurately diagnose suicidal ideation in first-episode drug-naïve MDD patients?
Case-Control (n=159)
Does a serum biomarker panel (AAT, TRSF, HDLC, APOA1) accurately diagnose suicidal ideation in first-episode drug-naïve MDD patients?
Effect estimate: AUC 0.994 (training) and 0.990 (testing)
A panel of four serum biomarkers (AAT, TRSF, HDLC, APOA1) shows high diagnostic accuracy for identifying suicidal ideation in first-episode drug-naïve MDD patients.
May support lipid/CRP profiling for SI risk stratification in MDD; leaves open diagnostic adoption pending validation.
BACKGROUND: Major depressive disorder (MDD) and suicide are two major health problems, but there are still no objective methods to diagnose MDD or suicidal ideation (SI). This study was conducted to identify potential biomarkers for diagnosing MDD patients with SI. METHODS: First-episode drug-naïve MDD patients with SI and demographics-matched healthy controls (HCs) were recruited. First-episode drug-naïve MDD patients without SI were also included. The serum lipids, C-reactive protein (CRP), transferring (TRSF), homocysteine (HCY) and alpha 1-antitrypsin (AAT) in serum were detected. The univariate and multivariate statistical analyses were used to identify and validate the potential biomarkers. RESULTS: The 86 HCs, 53 MDD patients with SI and 20 MDD patients without SI were included in this study. Four potential biomarkers were identified: AAT, TRSF, high-density lipoprotein cholesterol (HDLC), and apolipoprotein A1 (APOA1). After one month treatment, the levels of AAT and APOA1 were significantly improved. The panel consisting of these potential biomarkers had an excellent diagnostic performance, yielding an area under the ROC curve (AUC) of 0.994 and 0.990 in the training and testing set, respectively. Moreover, this panel could effectively distinguish MDD patients with SI from MDD patients without SI (AUC=0.928). CONCLUSION: These results showed that these potential biomarkers could facilitate the development of an objective method for diagnosing MDD patients with SI, and the decreased AAT levels in MDD patients might lead to the appearance of SI by resulting in the elevated inflammation.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2021) conducted a case-control in Major Depressive Disorder with Suicidal Ideation (n=159). Serum biomarker panel (AAT, TRSF, HDLC, APOA1) vs. Healthy controls and MDD patients without suicidal ideation was evaluated on Diagnostic performance (AUC) for identifying MDD patients with suicidal ideation (AUC 0.994 (training) and 0.990 (testing)). A serum biomarker panel consisting of AAT, TRSF, HDLC, and APOA1 effectively distinguished MDD patients with suicidal ideation from those without suicidal ideation (AUC 0.928).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: